江汉大学学报(自然科学版) ›› 2017, Vol. 45 ›› Issue (3): 247-250.doi: 10.16389/j.cnki.cn42-1737/n.2017.03.010

• 医学 • 上一篇    下一篇

替格瑞洛和氯吡格雷治疗急性缺血性脑卒中患者血小板参数变化比较

罗君1,陈国华*2   

  1. 1. 江汉大学 医学院,湖北 武汉 430056;2. 武汉市第一医院 神经内科,湖北 武汉 430022
  • 出版日期:2017-06-28 发布日期:2017-06-30
  • 通讯作者: 陈国华
  • 作者简介:罗君(1986—),女,硕士生,研究方向:神经内科。

Changes of Platelet Parameters in Patients of Acute Ischemic Cerebral Apoplexy Treated with Ticagrelor and Clopidogrel

LUO Jun1,CHEN Guohua*2   

  1. 1. School of Medicine,Jianghan University,Wuhan 430056,Hubei,China;2. Wuhan No. 1 Hospital,Wuahn 430022,Hubei,China
  • Online:2017-06-28 Published:2017-06-30
  • Contact: CHEN Guohua

摘要: 目 的 比较替格瑞洛和氯吡格雷治疗急性缺血性脑卒中患者血小板参数变化。方 法 选取2015年1 月-2016 年12 月武汉市第一医院24 h 内急性轻型脑卒中患者65 例,随机分为替格瑞洛及氯吡格雷组,分别评价用药前,用药后7 d,用药3个月后的血小板参数变化,包括PLT(血小板计数)、PCT(血小板压积)、PDW (血小板分布宽度)、MPV(血小板平均体积)。结 果 7 d及90 d氯吡格雷组与替格瑞洛组均能增加血小板分布宽度,分别为5%、2%,差异具有统计学意义( P < 0. 05)。两组出血事件或其他不良反应发生率、PLT(血小板计数)、PDW(血小板分布宽度)、PCT(血小板压积)及MPV(单个血小板平均体积)差异无统计学意义( P > 0. 05)。结 论 替格瑞洛较氯吡格雷增加血小板宽度幅度低,能更好地抑制血小板活化,从而更好地抗血小板聚集,不增加出血事件等不良事件,有望代替氯吡格雷成为治疗急性缺血性脑卒中且抗血小板聚集的一线用药。

关键词: 脑卒中, 氯吡格雷, 替格瑞洛, 血小板参数

Abstract: Objective To compare changes of platelet parameters in patients with acute ischemic cerebral apoplexy who have been treated with ticagrelor and clopidogrel. Methods The authors have chosen 65 cases of patients with acute ischemic cerebral apoplexy within 24 hours in Wuhan No. 1 Hospital from January 2015 to December 2016,who were randomly divided into ticagrelor group and clopidogrel group. Changes of platelet parameters were then evaluated before treatment,7 days and 3 months after treatment,including PLT(platelet count ),PCT(platelet hematocrit),PDW(platelet distribution width) and MPV(mean platelet volume). Results PDW increased both in clopidogrel group and ticagrelor group 7 days and 90 days after treatment,the growths were 5% and 2%,respectively. The difference was statistically significant( P < 0. 05). Rates of bleeding events or other adverse reactions,PLT,PDW,PCT and MPV of the two groups showed no significant difference( P > 0. 05). Conclusion Compared with clopidogrel,ticagrelor increases platelet width with low amplitude,thereby has better effect on anti- activation and anti- aggregation of platelet,and do not increase bleeding and otheradverse events,it is expected to become the first- line drugs instead of clopidogrel on platelet aggregation.

Key words: cerebral apoplexy, clopidogrel, ticagrelor, platelet parameter

中图分类号: